Expansion of Neuromuscular Care and Research for Children in Leeds

New investment aims to enhance treatment and research for neuromuscular disorders

The Leeds Children’s Neuromuscular (NM) service, recognised as a national centre of excellence for conditions such as Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA), is set to expand its clinical and research activities. This development seeks to sustain and improve the care provided to children with these complex conditions while increasing participation in national initiatives focused on optimising patient outcomes.

Details of the expansion

The investment will fund additional consultant time and the appointment of a Clinical Trials Coordinator. These roles are intended to support the management and delivery of complex clinical trials, including advanced gene therapy studies. The expansion is expected to:

• Increase the capacity for clinical trials within the service
• Enhance patient care through improved service delivery
• Strengthen Leeds’ leadership and involvement in neuromuscular research
• Boost recruitment of patients into clinical trials

Collaborative efforts

The initiative is supported through matched funding from Duchenne UK, a charity focused on improving the lives of those affected by Duchenne Muscular Dystrophy. This partnership aims to ensure ongoing advancements in both clinical care and research.

Impact on patients and research

The additional resources will facilitate increased trial activity and contribute to important research outputs. These developments are intended to improve patient experiences and outcomes by providing access to cutting-edge treatments and therapies under investigation.

Lead Researcher Dr Anne-Marie Chil… [Note: full name and details not provided in source]

For further information, please visit the Leeds Hospitals Charity website.